Status:
RECRUITING
Artemis Sleep Countermeasures
Lead Sponsor:
National Aeronautics and Space Administration (NASA)
Conditions:
Fatigue
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Purpose. The purpose of this study is to test sleep and wake-promoting countermeasures to evaluate their effectiveness in helping individuals fall asleep quickly, maintain sleep during a nap, and main...
Detailed Description
SPECIFIC AIMS The investigators aim to test whether pink noise can improve sleep outcomes and subsequent alertness. The investigators further aim to test whether pink noise induced sleep improves aler...
Eligibility Criteria
Inclusion
- Healthy individuals between the ages of 18 and 60
- Individuals who are pre-menopausal must be at least six months post-partum, not breastfeeding, and not planning a pregnancy in the immediate future.
Exclusion
- BMI \> 30
- A sleep disorder of any kind
- A chronic condition that could influence sleep (e.g., mood disorders, eye disorders)
- A chronic condition that would interfere with data collection and/or potentially make sleep deprivation unsafe (e.g., cardiovascular disorders, diabetes, cancer)
- Sensitive skin that would make electrode application intolerable
- Use of medication that interferes with sleep (e.g., anti-anxiety, antihistamines, antidepressants, beta blockers)
- Travel out of the time zone or stayed up all night in the past month
- Individuals who are pregnant.
- Individuals with a history of serious chronic conditions or mental illness. It is not possible to list all chronic conditions that may be exclusionary due to the number of medical conditions that would cause an individual to be ineligible. In brief, history of heart failure/disease, cancer, diabetes, seizures, respiratory diseases, sleep disorders, and Lupus are examples of conditions that would be considered exclusionary.
- Individuals who test positive for caffeine, alcohol, nicotine, amphetamines, barbiturates, benzodiazepines, cocaine, marijuana, MDMA (ecstasy), methadone, methamphetamines, opiates, oxycodones.
Key Trial Info
Start Date :
June 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06531733
Start Date
June 22 2024
End Date
June 1 2025
Last Update
August 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NASA Ames Research Center
Mountain View, California, United States, 94043